Wu C, Feng ML, Jiao TW, Sun MJ. Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer. World J Clin Cases 2022; 10(14): 4368-4379 [PMID: 35663086 DOI: 10.12998/wjcc.v10.i14.4368]
Corresponding Author of This Article
Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscope, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. sunydyy@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2022; 10(14): 4368-4379 Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4368
Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer
Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun
Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun, Department of Endoscope, The First Hospital Affiliated to China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Wu C and Sun MJ designed the research study; Feng ML and Jiao TW performed the research; Wu C and Feng ML contributed new reagents and analytic tools; Wu C and Jiao TW analyzed the data and wrote the manuscript; Wu C has received research funding; and all authors have read and approved the final manuscript.
Supported bythe Natural Science Foundation of Liaoning Province, No. 2019-BS-279.
Institutional review board statement: This study was approved by the Institutional Review Board of The First Affiliated Hospital of China Medical University (No. 2021-68-2).
Clinical trial registration statement: This study is registered at clinical hospital center “The First Hospital Affiliated to China Medical University” trial registry. The registration identification number is No. 2021-68-2.
Informed consent statement: Informed consent statement was waived.
Conflict-of-interest statement: There are no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscope, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. sunydyy@163.com
Received: August 2, 2021 Peer-review started: August 2, 2021 First decision: September 4, 2021 Revised: September 17, 2021 Accepted: March 25, 2022 Article in press: March 25, 2022 Published online: May 16, 2022 Processing time: 283 Days and 16.6 Hours
Core Tip
Core Tip: Drugs targeting mitochondria can induce mitophagy in colorectal cancer (CRC) cells and restrain cancer cells proliferation. Phosphoglycerate mutase family member 5 (PGAM5) can activate PTEN-induced putative kinase 1/Parkin pathway-mediated mitophagy. In this study, we explored 100 patients with advanced CRC to assess the expression and clinical potential of PGAM5 and Parkin proteins using immunohistochemistry. We found that both PGAM5 and Parkin protein expression has diagnostic significance for CRC and may become new biomarkers. Meanwhile, PGAM5 protein and mitophagy-related protein Parkin expression were significantly positively correlated and reduced Parkin protein expression was prognostic for shorter survival. Our data provide a promising foundation for increasing the accuracy of clinical judgment.
